Navigation Links
York U researchers uncovering how ovarian cancer resists chemotherapy
Date:3/2/2011

TORONTO, March 2, 2011 York University researchers have zeroed in on a genetic process that may allow ovarian cancer to resist chemotherapy.

Researchers in the university's Faculty of Science & Engineering studied a tiny strand of our genetic makeup known as a MicroRNA, involved in the regulation of gene expression. Cancer occurs when gene regulation goes haywire.

"Ovarian cancer is a very deadly disease because it's hard to detect," says biology professor Chun Peng, who co-authored the study. By the time it's diagnosed, usually it is in its late stages. And by that point there's really no way to treat the disease. Even when the disease is discovered in its early stages, chemotherapy doesn't always work," she says.

Peng was among a team of researchers that discovered a receptor, ALK7, that induces cell-death in epithelial ovarian cancer cells. They have now discerned that microRNA 376c targets this crucial receptor, inhibiting its expression and allowing ovarian cancer cells to thrive.

"Our evidence suggests that microRNA 376c is crucial to determining how a patient will respond to a chemotherapeutic agent," says Peng. "It allows cancer cells to survive by targeting the very process that kills them off," she says.

In examining tumours taken from patients who were non-responsive to chemotherapy, researchers found a higher expression of microRNA 376c and a much lower expression of ALK7.

Peng believes that this research is a step towards being able to make chemotherapy drugs more effective in the treatment of the disease.

"Further study is needed, but ultimately if we can introduce anti-microRNAs that would lower the level of those microRNAs that make cancer cells resistant to chemotherapeutic drugs, we will be able to make chemotherapy more effective against ovarian cancer," Peng says.

She urges women to educate themselves about the risk factors and symptoms of the disease. For more information, visit http://www.ovariancanada.org .

Peng is a world expert in the area of ovarian cancer and the molecular basis of complications in pregnancy. Her research on chemo-resistance has also contributed to knowledge and prediction of pre-eclampsia, a pregnancy disorder that is a leading cause of maternal and perinatal complications and death.

The article, "MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance," was published in the Journal of Cell Science.


'/>"/>

Contact: Melissa Hughes
mehughes@yorku.ca
416-736-2100 x22097
York University
Source:Eurekalert

Related biology news :

1. Researchers predict age of T cells to improve cancer treatment
2. Researchers looking at a rare disease make breakthrough that could benefit everyone
3. Researchers develop curious snapshot of powerful retinal pigment and its partners
4. 20 researchers selected as 2011 Leopold Leadership Fellows
5. Researchers from Hebrew U., US discover how mercury gets into fish we eat
6. Canadian researchers first worldwide to generate pluripotent stem cells from horses
7. Researchers have found how brain cells control their movement to form the cerebral cortex
8. Cleveland Clinic researchers honored for contributions to science and technology
9. UT researchers crack code to harmful brown tides
10. Iowa State, Ames Lab researchers describe the pump that bacteria use to resist drugs
11. Researchers achieve a full film frame of a family of proteins essential for cell function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... This report analyzes the worldwide markets for Biostimulants ... Amino, & Fulvic), Extract Based, and Others. The report also ... & Turf, Row Crops, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and forecasts are ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... of innovation is taking over sports. On Thursday, December 15th a panel of ... is disrupting the playing field at a Smart Talk session. Smart Talk will ...
(Date:12/8/2016)... 8, 2016  Renova™ Therapeutics, a biotechnology company ... and type 2 diabetes, announced that it has ... virus (AAV) vector developed in the laboratory of ... Stanford University. The company plans to use this ... product pipeline. "Early research has ...
(Date:12/8/2016)... Portland, Oregon (PRWEB) , ... December 08, 2016 ... ... modules and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or ... do not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module ...
Breaking Biology Technology: